C-reactive protein, interleukin 6 and lung cancer risk: A meta-analysis

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Zhou, Bo ^a,b   Liu, Jing ^b   Wang, Ze Mu ^c   Xi, Tao ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANJING TECH UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6;

ARTICLE; CANCER RISK; DISEASE ASSOCIATION; EMBASE; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; MEDLINE; PROTEIN ANALYSIS; RISK ASSESSMENT; SEX DIFFERENCE; SYSTEMATIC REVIEW;

C-REACTIVE PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; INTERLEUKIN-6; LUNG NEOPLASMS; MALE; RISK FACTORS; SEX FACTORS;

EID: 84865101477     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043075     Document Type: Article

References (46)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
3. Thun MJ, Henley SJ, Calle EE, (2002) Tobacco use and cancer: an epidemiologic perspective for geneticists. Oncogene 21: 7307-7325.
4. Ballaz S, Mulshine JL, (2003) The potential contributions of chronic inflammation to lung carcinogenesis. Clin Lung Cancer 5: 46-62.
5. Engels EA, (2008) Inflammation in the development of lung cancer: Epidemiological evidence. Expert Rev Anticancer Ther 8: 605-615.
6. Schottenfeld D, Beebe-Dimmer J, (2006) Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin 56: 69-83.
7. Engels EA, Wu X, Gu J, Dong Q, Liu J, et al. (2007) Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. Cancer Res 67: 6520-6527.
8. Gabay C, Kushner I, (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340: 448-454.
9. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH, (1998) Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98: 731-733.
10. Tsilidis KK, Branchini C, Guallar E, Helzlsouer KJ, Erlinger TP, et al. (2008) C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int J Cancer 123: 1133-1140.
11. Brichory FM, Misek DE, Yim AM, Krause MC, Giordano TJ, et al. (2001) An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A 98: 9824-9829.
12. Heikkilä K, Harris R, Lowe G, Rumley A, Yarnell J, et al. (2009) Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 20: 15-26.
13. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
14. Greenland S, Longnecker MP, (1992) Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 135: 1301-1309.
15. Orsini N, Bellocco R, Greenland S, (2006) Generalized least squares for trend estimation of summarized dose-response data. Stata J 6: 40-57.
16. Higgins JP, Thompson SG, (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558.
17. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
18. Lee S, Choe JW, Kim HK, Sung J, (2011) High-sensitivity C-reactive protein and cancer. J Epidemiol 21: 161-168.
19. Alifano M, Falcoz PE, Seegers V, Roche N, Schussler O, et al. (2011) Preresection serum C-reactive protein measurement and survival among patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg 142: 1161-1167.
20. Hara M, Yonei A, Ayabe T, Tomita M, Nakamura K, et al. (2010) Postoperative serum C-reactive protein levels in non-small cell lung cancer patients. Ann Thorac Cardiovasc Surg 16: 85-90.
21. Kasymjanova G, MacDonald N, Agulnik JS, Cohen V, Pepe C, et al. (2010) The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer. Curr Oncol 17: 52-58.
22. O'Dowd C, McRae LA, McMillan DC, Kirk A, Milroy R, (2010) Elevated preoperative C-reactive protein predicts poor cancer specific survival in patients undergoing resection for non-small cell lung cancer. J Thorac Oncol 5: 988-992.
23. Gagnon B, Abrahamowicz M, Xiao Y, Beauchamp ME, MacDonald N, et al. (2010) Flexible modeling improves assessment of prognostic value of C-reactive protein in advanced non-small cell lung cancer. Br J Cancer 102: 1113-1122.
24. Koch A, Fohlin H, Sörenson S, (2009) Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy. J Thorac Oncol 4: 326-332.
25. Wilop S, Crysandt M, Bendel M, Mahnken AH, Osieka R, et al. (2008) Correlation of C-reactive protein with survival and radiographic response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer. Onkologie 31: 665-670.
26. Hara M, Matsuzaki Y, Shimuzu T, Tomita M, Ayabe T, et al. (2007) Preoperative serum C-reactive protein level in non-small cell lung cancer. Anticancer Res 27: 3001-3004.
27. Scott HR, McMillan DC, Watson WS, Milroy R, McArdle CS, (2001) Longitudinal study of resting energy expenditure, body cell mass and the inflammatory response in male patients with non-small cell lung cancer. Lung Cancer 32: 307-312.
28. Yanagawa H, Sone S, Takahashi Y, Haku T, Yano S, et al. (1995) Serum levels of interleukin 6 in patients with lung cancer. Br J Cancer 71: 1095-1098.
29. Il'yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, et al. (2005) Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 14: 2413-2418.
30. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P, (2006) Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev 15: 381-384.
31. Suzuki K, Ito Y, Wakai K, Kawado M, Hashimoto S, et al. (2006) Serum heat shock protein 70 levels and lung cancer risk: a case-control study nested in a large cohort study. Cancer Epidemiol Biomarkers Prev 15: 1733-1737.
32. Siemes C, Visser LE, Coebergh JW, Splinter TA, Witteman JC, et al. (2006) C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol 24: 5216-5222.
33. Allin KH, Bojesen SE, Nordestgaard BG, (2009) Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 27: 2217-2224.
34. dos Santos Silva I, De Stavola BL, Pizzi C, Meade TW, (2010) Circulating levels of coagulation and inflammation markers and cancer risks: individual participant analysis of data from three long-term cohorts. Int J Epidemiol 39: 699-709.
35. Chaturvedi AK, Caporaso NE, Katki HA, Wong HL, Chatterjee N, et al. (2010) C-reactive protein and risk of lung cancer. J Clin Oncol 28: 2719-2726.
36. Van Hemelrijck M, Holmberg L, Garmo H, Hammar N, Walldius G, et al. (2011) Association between levels of C-reactive protein and leukocytes and cancer: three repeated measurements in the Swedish AMORIS study. Cancer Epidemiol Biomarkers Prev 20: 428-437.
37. Pine SR, Mechanic LE, Enewold L, Chaturvedi AK, Katki HA, et al. (2011) Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst 103: 1112-1122.
38. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for ystematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 51: 264-269, W264.
39. Heikkilä K, Ebrahim S, Lawlor DA, (2007) A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health 61: 824-833.
40. Engels EA, (2008) Inflammation in the development of lung cancer: Epidemiological evidence. Expert Rev Anticancer Ther 8: 605-615.
41. Littman AJ, Jackson LA, Vaughan TL, (2005) Chlamydia pneumoniae and lung cancer: Epidemiologic evidence. Cancer Epidemiol Biomarkers Prev 14: 773-778.
42. Yu YY, Pinsky PF, Caporaso NE, Chatterjee N, Baumgarten M, et al. (2008) Lung cancer risk following detection of pulmonary scarring by chest radiography in the prostate, lung, colorectal, and ovarian cancer screening trial. Arch Intern Med 168: 2326-2332.
43. Travis WD, Rekhtman N, (2011) Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing. Semin Respir Crit Care Med 32: 22-31.
44. Enewold L, Mechanic LE, Bowman ED, Zheng YL, Yu Z, et al. (2009) Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 18: 215-222.
45. Ara T, Declerck YA, (2010) Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer 46: 1223-1231.
46. Mojtahedi Z, Khademi B, Hashemi SB, Abtahi SM, Ghasemi MA, et al. (2011) Serum interleukine-6 concentration, but not interleukine-18, is associated with head and neck squamous cell carcinoma progression. Pathol Oncol Res 76: 7-10.